Schrodinger, Inc. SDGR shares ended the last trading session 14.1% higher at $24.34. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 8.1% gain over the past four weeks.
Schrodinger recorded a strong price rise on investors’ optimism surrounding the company’s announcement of its strategic priorities for 2025. The company also provided an update on its progress across the business in 2024. The company’s 2024 achievements included a multi-target research collaboration and license agreement with Novartis.
This company is expected to post quarterly loss of $0.25 per share in its upcoming report, which represents a year-over-year change of +21.9%. Revenues are expected to be $84.93 million, up 14.6% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Schrodinger, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on SDGR going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Schrodinger is part of the Zacks Medical Info Systems industry. Fulgent Genetics, Inc. FLGT, another stock in the same industry, closed the last trading session 3.8% lower at $16.96. FLGT has returned -4.8% in the past month.
For Fulgent Genetics
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.1% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>Schrodinger, Inc. (SDGR) : Free Stock Analysis Report
Fulgent Genetics, Inc. (FLGT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
